Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endocrine Treatment Alone for Elderly Patients With ER+ Breast Cancer
NCT02476786Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2017
- Primary completion
- Jan 2027
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of goserelin, anastrozole, letrozole, exemestane, fulvestrant in breast cancer, sponsored by Washington University School of Medicine. Started Jan 2017; status: recruiting.
02
Drugs
goserelinanastrozoleletrozoleexemestanefulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02476786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02476786.